Christopher Joseph Aquino
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher Joseph Aquino.
Journal of Medicinal Chemistry | 2013
Yulin Wu; Christopher Joseph Aquino; David John Cowan; Don L. Anderson; Jeff L. Ambroso; Michael J. Bishop; Eric E. Boros; Lihong Chen; Alan Cunningham; Robert L. Dobbins; Paul L. Feldman; Lindsey T. Harston; Istvan Kaldor; Ryan Klein; Xi Liang; Maggie S. McIntyre; Christine L. Merrill; Kristin M. Patterson; Judith S. Prescott; John S. Ray; Shane Roller; Xiaozhou Yao; Andrew A. Young; Josephine Yuen; Jon L. Collins
The apical sodium-dependent bile acid transporter (ASBT) transports bile salts from the lumen of the gastrointestinal (GI) tract to the liver via the portal vein. Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. While modest lipid effects were demonstrated, the potential utility of ASBT inhibitors for treatment of type 2 diabetes has been relatively unexplored. We initiated a lead optimization effort that focused on the identification of a potent, nonabsorbable ASBT inhibitor starting from the first-generation inhibitor 264W94 (1). Extensive SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent, nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.
Journal of Medicinal Chemistry | 2008
Wieslaw M. Kazmierski; Christopher Joseph Aquino; Brian A. Chauder; Felix Deanda; Robert M. Ferris; Deborah K. Jones-Hertzog; Terrence P. Kenakin; Cecilia S. Koble; Christian Watson; Pat Wheelan; Hanbiao Yang; Michael Youngman
We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the (125)I-[MIP-1beta] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC 50 = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC 50 = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.
Journal of Biological Chemistry | 2017
Jon Paczkowski; Sampriti Mukherjee; Amelia R. McCready; Jian-Ping Cong; Christopher Joseph Aquino; Hahn Kim; Brad R. Henke; Chari Smith; Bonnie L. Bassler
Quorum sensing is a process of cell-cell communication that bacteria use to regulate collective behaviors. Quorum sensing depends on the production, detection, and group-wide response to extracellular signal molecules called autoinducers. In many bacterial species, quorum sensing controls virulence factor production. Thus, disrupting quorum sensing is considered a promising strategy to combat bacterial pathogenicity. Several members of a family of naturally produced plant metabolites called flavonoids inhibit Pseudomonas aeruginosa biofilm formation by an unknown mechanism. Here, we explore this family of molecules further, and we demonstrate that flavonoids specifically inhibit quorum sensing via antagonism of the autoinducer-binding receptors, LasR and RhlR. Structure-activity relationship analyses demonstrate that the presence of two hydroxyl moieties in the flavone A-ring backbone are essential for potent inhibition of LasR/RhlR. Biochemical analyses reveal that the flavonoids function non-competitively to prevent LasR/RhlR DNA binding. Administration of the flavonoids to P. aeruginosa alters transcription of quorum sensing-controlled target promoters and suppresses virulence factor production, confirming their potential as anti-infectives that do not function by traditional bacteriocidal or bacteriostatic mechanisms.
Journal of Medicinal Chemistry | 1996
Christopher Joseph Aquino; Duncan R. Armour; Judd Berman; Larry S. Birkemo; Robin Arthur Ellis Carr; Dallas K. Croom; Milana Dezube; Robert W. Dougherty; Gregory N. Ervin; Mary K. Grizzle; Julie E. Head; Gavin Charles Hirst; Michael K James; Michael F. Johnson; Laurence J. Miller; Kennedy L. Queen; Thomas J. Rimele; David N. Smith; Elizabeth E. Sugg
Journal of Medicinal Chemistry | 1997
Brad R. Henke; Christopher Joseph Aquino; Larry S. Birkemo; Dallas K. Croom; Robert W. Dougherty; Gregory N. Ervin; Mary K. Grizzle; Gavin Charles Hirst; Michael K. James; Michael F. Johnson; Kennedy L. Queen; Ronald G. Sherrill; Elizabeth E. Sugg; Edward Martin Suh; Jerzy W. Szewczyk; Rayomand Jal Unwalla; Jeff Yingling; Timothy M. Willson
Archive | 2003
Wieslaw M. Kazmierski; Christopher Joseph Aquino; Neil Bifulco; Eric E. Boros; Brian Andrew Chauder; Pek Yoke Chong; Maosheng Duan; Jr. Felix Deanda; Cecilia S. Koble; Ed W. McLean; Jennifer Poole Peckham; Angilique C Perkins; James B. Thompson; Dana Vanderwall
Journal of Medicinal Chemistry | 1996
Gavin Charles Hirst; Christopher Joseph Aquino; Lawrence Birkemo; Dallas K. Croom; Milana Dezube; Robert W. Dougherty; Gregory N. Ervin; Mary K. Grizzle; Brad R. Henke; Michael K. James; Michael F. Johnson; Tanya Momtahen; Kennedy L. Queen; Ronald George Sherrill; Jerzy Ryszard Szewczyk; Timothy M. Willson; Elizabeth E. Sugg
Archive | 2003
Maosheng Duan; Wieslaw M. Kazmierski; Christopher Joseph Aquino
Archive | 1995
Christopher Joseph Aquino; Elizabeth E. Sugg; Jerzy Ryszard Szewczyk
Archive | 2003
Hanbiao Yang; Wieslaw Mieczyslaw GlaxoSmithKline Kazmierski; Christopher Joseph Aquino